Lobaplatin Enhances Radioactive 125I Seed-Induced Apoptosis and Anti-Proliferative Effect in Non-Small Cell Lung Cancer by Suppressing the AKT/mTOR Pathway
Jia-hui Rong,Dong Li,Yu-liang Li
DOI: https://doi.org/10.2147/ott.s288012
IF: 4
2021-01-12
OncoTargets and Therapy
Abstract:Jia-hui Rong, 1 Dong Li, 2 Yu-liang Li 2 1 Department of Cardiology, The Second Hospital of Shandong University, Jinan, People's Republic of China; 2 Department of Interventional Medicine, The Second Hospital of Shandong University, Jinan, People's Republic of China Correspondence: Dong Li; Yu-liang Li Department of Interventional Medicine, The Second Hospital of Shandong University, 247 Beiyuan Street, Jinan 250000, People's Republic of China Email 714048127@qq.com; lyl.pro@sdu.edu.cn Introduction: In recent years, radioactive 125 I seed implantation combined with chemotherapy has been regarded as a safe and effective treatment for advanced non-small cell lung cancer (NSCLC). However, the mechanism underlying this success is still unclear. Methods: In this study, we investigated the apoptosis and anti-proliferative effect induced by 125 I in A549, H1975, and H157 cells and determined whether a sensitizing concentration of lobaplatin (LBP) could enhance these effects. We performed in vitro experiments on A549, H1975, and H157 cells; we investigated the effects of 125 I or lobaplatin (LBP) alone, or in combination, on cellular apoptosis and proliferation by performing flow cytometry, Bax/Bcl2 ratio, TUNEL, cell viability assay, cell cycle, and EdU. To further verify our findings, a subcutaneous tumor mouse model was established. Moreover, AKT/mTOR pathway was detected to determine whether this pathway was involved in the anti-cancer effect of 125 I and LBP by up-regulating or down-regulating the expression of mTOR. Results: Based on our results, the sensitizing concentration of LBP could enhance the 125 I-induced apoptosis and anti-proliferation effect. Furthermore, the subcutaneous tumor mouse model obtained the consistent results. More importantly, the AKT/mTOR pathway was down-regulated after the treatment of 125 I and LBP, and the anti-cancer effect of 125 I and LBP could be compromised by up-regulating the mTOR expression. Conclusion: Our study proved that LBP promotes the apoptotic and anti-proliferative effects of 125 I in NSCLC cells by inhibiting the AKT/mTOR pathway and provides a foundation for future studies and enhanced combinatorial approaches for NSCLC in the clinical setting. Keywords: radioactive 125 I seed, lobaplatin, non-small cell lung cancer, apoptosis, proliferation, AKT/mTOR pathway
oncology,biotechnology & applied microbiology